The Chinese Clinical Trial Registry (ChiCTR), a WHO‑recognized primary registry, just posted a fresh batch of more than a dozen studies, all entered on September 5, 2026. This public database lets researchers, doctors, and the public see what medical investigations are underway across China, from hospitals to research institutes. Among the newest entries are an interventional trial testing a knowledge‑translation model to keep ICU patients on enteral nutrition, a collaborative early‑drug‑development project between Chinese and Japanese hospitals, and a smart‑management program aimed at reducing frailty in older adults. Cutting‑edge imaging research also appears, with a PET/CT scan using a novel tracer to target FGFR2b in gastric cancer patients. Other studies explore practical clinical tools, such as a decision‑support system for PICC line placement, prophylactic pancreatic stents to lower complications after duodenal tumor removal, and special corrective lenses for people with anisometropia. The registry also lists observational work on a rare kidney disease linked to MYO1E mutations, a phase‑II trial of a new drug combo for SMARCA4‑deficient lung cancer, and a brain‑computer‑interface dataset for post‑stroke monitoring. In total, the platform now houses 129,247 registered trials, offering transparency and a window into the breadth of medical research happening across the nation.
Read more